Equity Overview
Price & Market Data
Price: $3.50
Daily Change: +$0.02 / 0.57%
Range: $3.36 - $3.51
Market Cap: $60,166,416
Volume: 3,969
Performance Metrics
1 Week: 17.97%
1 Month: 67.31%
3 Months: 63.38%
6 Months: 185.3%
1 Year: 8.41%
YTD: 58.18%
Details
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.